Author Page for Sidna M. Tulledge-Scheitel

Actions:

View:
Selected
Original List
All Versions Hide All Versions
All Abstracts Hide All Abstracts

(Rank)

Casirivimab-Imdevimab Treatment Is Associated with Reduced Rates of Hospitalization Among High-Risk Patients with Mild to Moderate Coronavirus Disease-19

Number of pages: 25 Posted: 01 Jun 2021

Raymund R. Razonable, Colin Pawlowski, John C. O'Horo, Lori L. Arndt, Richard Arndt, Dennis M. Bierle, Molly Destro Borgen, Sara N. Hanson, Michelle C. Hedin, Patrick Lenehan, Arjun Puranik, Leigh L. Speicher, Maria Seville, Sidna M. Tulledge-Scheitel, AJ Venkatakrishnan, Caroline G. Wilker, Andrew D. Badley and Ravindra Ganesh

Mayo Clinic, nference, Inc., Mayo Clinic, Mayo Clinic, Independent, Mayo Clinic, Mayo Clinic, Mayo Clinic, Mayo Clinic, nference, Inc., nference, Inc., Mayo Clinic, Mayo Clinic, Mayo Clinic - College of Medicine and Science, nference, Inc., Mayo Clinic, Mayo Clinic and Mayo Clinic

Downloads 135 (540,814)

Citation 4

Abstract:

Evaluating Health Plan Benefit Change: A Finite Mixture Model Approach

iHEA 2007 6th World Congress: Explorations in Health Economics Paper

Posted: 20 Jun 2007

Nilay Shah, Benjamin M. Craig, Ritesh Banerjee, Sidna M. Tulledge-Scheitel and James Naessens

Mayo Clinic - College of Medicine and Science, University of Wisconsin-Madison - Department of Family Medicine, affiliation not provided to SSRN, Mayo Clinic - College of Medicine and Science and Mayo Clinic - College of Medicine and Science

Sidna M. Tulledge-Scheitel

Mayo Clinic - College of Medicine and Science

2

135

4

Scholarly Papers (2)

Casirivimab-Imdevimab Treatment Is Associated with Reduced Rates of Hospitalization Among High-Risk Patients with Mild to Moderate Coronavirus Disease-19

Abstract:

Evaluating Health Plan Benefit Change: A Finite Mixture Model Approach

Abstract: